{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Malignant+Neoplasm", "query": { "condition": "Non-Malignant Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1333, "total_pages": 134, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Malignant+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T17:45:40.671Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT04628780", "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07209960", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-12-16", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628780" }, { "nct_id": "NCT06712810", "title": "Q702 for the Treatment of Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Histiocytic Sarcoma", "Malignant Histiocytosis", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Follicular Lymphoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelofibrosis", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Erdheim-Chester Disease", "Refractory Follicular Lymphoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Myelodysplastic Syndrome", "Refractory Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Rosai-Dorfman-Destombes Disease", "Primary Central Nervous System Lymphoma", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Erdheim-Chester Disease", "Recurrent Fibroblastic Reticular Cell Sarcoma", "Recurrent Histiocytic Sarcoma", "Recurrent Interdigitating Dendritic Cell Sarcoma", "Recurrent Rosai-Dorfman-Destombes Disease", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Fibroblastic Reticular Cell Sarcoma", "Refractory Histiocytic Sarcoma", "Refractory Interdigitating Dendritic Cell Sarcoma", "Refractory Rosai-Dorfman-Destombes Disease" ], "interventions": [ { "name": "Axl/Mer/CSF1R Inhibitor Q702", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2025-08-27", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712810" }, { "nct_id": "NCT04079179", "title": "Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Langerhan's Cell Histiocytosis", "Juvenile Xanthogranuloma", "Erdheim-Chester Disease", "Rosai Dorfman Disease", "Neuro-Degenerative Disease", "Histiocytic Sarcoma", "Histiocytic Disorders, Malignant" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carl Allen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 90, "start_date": "2021-04-19", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04079179" }, { "nct_id": "NCT00424242", "title": "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Metastatic Cancer", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Secondary Myelofibrosis", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "2007-01", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2021-09-08", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424242" }, { "nct_id": "NCT05551117", "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostatic Cancer", "Androgen-Independent Prostatic Cancer", "Androgen-Insensitive Prostatic Cancer", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Anal Cancer", "Anal Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oral Squamous Cell Carcinoma", "Malignant Melanoma", "Melanoma", "Non-small Cell Lung Cancer", "Non-small Cell Carcinoma", "Small-cell Lung Cancer", "Small Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine 2.0 mg (Arm A)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine 2.7 mg (Arm B)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2023-06-13", "completion_date": "2025-01-23", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 14, "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05551117" }, { "nct_id": "NCT00020527", "title": "Caspofungin Acetate in Treating Children With Fever and Neutropenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fever, Sweats, and Hot Flashes", "Infection", "Kidney Cancer", "Leukemia", "Lymphoma", "Neuroblastoma", "Neutropenia", "Sarcoma" ], "interventions": [ { "name": "caspofungin acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": null, "start_date": "2001-03", "completion_date": "2003-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020527" }, { "nct_id": "NCT00402896", "title": "Malignant Pleural Effusion With ZD6474", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Pleural Effusion" ], "interventions": [ { "name": "ZD6474", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-03-09", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402896" }, { "nct_id": "NCT06208124", "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor (Phase 1)", "Pancreas Adenocarcinoma", "Non-small Cell Lung Cancer", "Malignant Melanoma (Cutaneous)" ], "interventions": [ { "name": "IMM-6-415", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immuneering Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-27", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208124" }, { "nct_id": "NCT01121588", "title": "Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms Malignant" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 44, "start_date": "2011-03-22", "completion_date": "2023-09-07", "has_results": true, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-07-22T17:45:40.671Z", "location_count": 9, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01121588" } ] }